Nebivolol in Patients With Systolic Stage 2 Hypertension
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of
nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.